Skip to content
Pharma Observatory a Scientist.com platform
  • Trial site

Trial site location from the registry's own city and country. GeoNames (geonames.org).

Clinical trial site

The Mark H Zangmeister Center

The Mark H Zangmeister Center in Columbus, Ohio, United States is listed as a site for 243 registered clinical trials, 133 of them ongoing.

Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Registered trials 243
Ongoing 133

This page covers the site record The Mark H Zangmeister Center in Columbus, Ohio, United States: the trials that list it by this name in ClinicalTrials.gov. The same place can be registered under other names, each with its own page and its own trials, and a count here is a number of registered trials, not of patients enrolled.

Get the The Mark H Zangmeister Center report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Trials by phase

Registered trials that list this site, by trial phase. 243 trials counted.

  • Phase 1 2 trials
  • Phase 1/2 6 trials
  • Phase 2 83 trials
  • Phase 2/3 17 trials
  • Phase 3 106 trials
  • Not applicable 12 trials
  • Observational 15 trials
  • Expanded access 1 trial
  • Unknown 1 trial

Trials by status

The registry's own status summary: Ongoing, Completed, Terminated or Other.

  • Ongoing 133 trials
  • Completed 78 trials
  • Terminated 17 trials
  • Other 15 trials

Trials over time

Trials registered with a start date in each year, 1990 onward, most recent years first.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Not applicable
  • Observational
  • Unknown

Top of scale: 31

2007: 4 trials (Unknown 1, Phase 3 3) 2008: 6 trials (Phase 3 4, Phase 2 2) 2009: 9 trials (Not applicable 1, Phase 3 8) 2010: 9 trials (Phase 3 6, Phase 2 2, Phase 1/2 1) 2011: 9 trials (Observational 1, Not applicable 1, Phase 3 7) 2012: 17 trials (Phase 3 7, Phase 2/3 1, Phase 2 6, Phase 1/2 3) 2013: 15 trials (Not applicable 2, Phase 3 5, Phase 2 8) 2014: 26 trials (Observational 1, Not applicable 1, Phase 3 9, Phase 2/3 6, Phase 2 8, Phase 1/2 1) 2015: 16 trials (Observational 1, Phase 3 7, Phase 2/3 2, Phase 2 6) 2016: 14 trials (Observational 1, Not applicable 1, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1/2 1) 2017: 15 trials (Phase 3 5, Phase 2/3 1, Phase 2 8, Phase 1 1) 2018: 19 trials (Observational 2, Not applicable 1, Phase 3 5, Phase 2 11) 2019: 31 trials (Observational 4, Phase 3 15, Phase 2/3 3, Phase 2 9) 2020: 15 trials (Observational 3, Phase 3 7, Phase 2 5) 2021: 16 trials (Observational 1, Not applicable 2, Phase 3 5, Phase 2/3 1, Phase 2 6, Phase 1 1) 2022: 8 trials (Observational 1, Phase 3 3, Phase 2/3 2, Phase 2 2) 2023: 7 trials (Phase 3 3, Phase 2 4) 2024: 5 trials (Not applicable 3, Phase 3 1, Phase 2 1) 2025: 1 trials (Phase 3 1)

Trials that list this site and are registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2025 1
2024 5
2023 7
2022 8
2021 16
2020 15
2019 31
2018 19
2017 15
2016 14

2026 is partial: trials registered with a 2026 start date so far, not a full year

Recent trials

The newest registered trials that list this site. Each title opens its ClinicalTrials.gov record.

Source: ClinicalTrials.gov

Lead sponsors

Most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Conditions studied

The specific conditions of the trials that list this site, most trials first.